Skip to main content

Table 1 Number, number-needed-to-treat/harm and relative benefit/risk estimate for placebo controlled clinical trials of rofecoxib 50 mg

From: Single-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic review

  

Number/total (%) with the outcome with

  

Outcome

Number of trials

Rofecoxib 50 mg

Placebo

Relative benefit/risk (95% CI)

NNT/H (95% CI)

At least 50% pain relief

5

(56)

(11)

4.8 (3.3 to 7.2)

2.3 (2.0 to 2.6)

Any adverse event

2

(28)

(33)

0.69 (0.44 to 1.08)

Not calculated

Nausea

3

(7)

(17)

0.48 (0.26 to 0.88)

-11 (-6 to -40)

Vomiting

3

(4)

(12)

0.36 (0.16 to 0.79)

-12 (-7 to -46)